19:05 , Mar 17, 2017 |  BioCentury  |  Finance

CRISPR pigs

Drawn by CRISPR’s potential to address the organ transplant shortage with safer xenotransplants, Biomatics Capital Partners and Arch Venture Partners co-led a $38 million series A round for eGenesis Inc. intended to fund the company...
08:00 , Feb 8, 2016 |  BioCentury  |  Finance

IPO holding pattern?

A heavy dose of built-in demand is at the root of the only two biotech IPOs completed so far this year. Editas Medicine Inc. (NASDAQ:EDIT) and BeiGene Ltd. (NASDAQ:BGNE) both priced their offerings within range...
08:00 , Feb 1, 2016 |  BioCentury  |  Finance

Valuing CRISPR/Cas9

Editas Medicine Inc. is looking for a $606.9 million postmoney valuation - the highest of any preclinical biotech IPO since BioCentury started tracking financings in 1994. Even if Editas takes the now-standard 20% IPO haircut,...
07:00 , Aug 17, 2015 |  BioCentury  |  Finance

Editors wanted

Deerfield Management has made an initial $20 million bet on CRISPR technology with Editas Medicine , but other gene editing companies shouldn't assume the firm is closed for business. The firm's investment was part of...
01:54 , Aug 11, 2015 |  BC Extra  |  Top Story

Editas raises $120M in series B

Genome editing company Editas Medicine (Cambridge, Mass.) raised $120 million in a series B round led by new investor bng0, a firm that represents multiple family offices including those of Bill Gates. Other new investors...